目的应用起立-行走计时测试(Timed Up and Go Test,TUGT)探究社区老年人群运动功能与情绪、认知、睡眠方面的相关性。方法横断面研究,2021年12月至2023年8月在中国北京市、天津市、浙江省、广东省、海南省随机招募60~90岁共739名受试者...
详细信息
目的应用起立-行走计时测试(Timed Up and Go Test,TUGT)探究社区老年人群运动功能与情绪、认知、睡眠方面的相关性。方法横断面研究,2021年12月至2023年8月在中国北京市、天津市、浙江省、广东省、海南省随机招募60~90岁共739名受试者,根据TUGT时间(t),将受试者分为运动正常组、运动轻度异常组和运动明显异常组。收集基本信息,并应用TUGT评估运动功能,中国修订的简易智力状态检查量表(Mini-mental State Examination,MMSE)评估认知功能,患者健康问卷抑郁量表(Patient health questionnaire-9,PHQ-9)评估抑郁程度,Epworth嗜睡量表(Epworth Sleepiness Scale,ESS)评估过度日间嗜睡程度。分析受试者运动功能与认知、情绪及睡眠的相关性。结果收缩压、心率、PHQ-9、MMSE、ESS得分是TUGT时间的影响因素。TUGT时间与PHQ-9及ESS得分呈正相关,与收缩压、心率、MMSE得分呈负相关,与MMSE子成分中定向力、即刻记忆力及语言能力呈负相关,差异均具有统计学意义(均P<0.05)。logistic回归分析显示:PHQ-9得分升高(运动轻度异常组OR=1.099,95%CI:1.045~1.155,P<0.001;运动明显异常组OR=1.150,95%CI:1.066~1.242,P<0.001)、MMSE得分降低(运动轻度异常组OR=0.939,95%CI:0.886~0.995,P<0.033;运动明显异常组OR=0.793,95%CI:0.729~0.862,P<0.001)、ESS得分升高(运动轻度异常组OR=1.139,95%CI:1.094~1.186,P<0.001;运动明显异常组OR=1.203,95%CI:1.132~1.279,P<0.001)与运动功能下降独立相关。结论抑郁状态、认知障碍及过度日间嗜睡与社区老年人群运动功能下降具有相关性,TUGT可用于社区老年人群的运动功能下降的早期筛查。
Objective To compare the effects of cilostazol on cerebral arteries and cerebrovascular blood flow in secondary prevention of ischemic stroke, with those of aspirin. Methods Sixty-eight patients who had ischemic strok...
详细信息
Objective To compare the effects of cilostazol on cerebral arteries and cerebrovascular blood flow in secondary prevention of ischemic stroke, with those of aspirin. Methods Sixty-eight patients who had ischemic stroke during the recent 1-6 months were recruited and randomized into cilostazol or aspirin group. Cerebrovascular condition was assessed by magnetic resonance angiography (MRA) and transcranial doppler ultrasonography (TCD) at the beginning of the study and after 12-month medication. Results During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found. MRA revealed that in aspirin group, the percentages of patients experiencing aggravation and attenuation of cerebrovascular condition were 3.3% and 6.7%, respectively, while in aspirin group, they were 3.3% and 10%, respectively. Moreover, TCD revealed that 26.9% of the patients in aspirin group and 14.3% of the patients in cilostazol group experienced aggravation of cerebrovascular condition. However, the systolic peak flow velocity of the previously abnormal arteries increased by 42.9% after 12-month medication of cilostazol, which was significantly higher than that after aspirin medication (27.5%) (P = 0.04). Furthermore, as a major side effect of antiplatelet therapy, the frequrency of bleeding was much less in cilostazol group (0 case in cilostazol group vs 5 in aspirin, P 〈 0.05). Conclusion Cilostazol is as effective as aspirin in preventing the aggravation of cerebral arteries in secondary prevention of ischemic stroke. Besides, it is more safe. Cilostazol can increase the systolic peak flow velocity of cerebral arteries, which may improve the blood supply of focal ischemia.
暂无评论